Login / Signup

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates.

Warren ViricelGuy FournetSabine BeaumelEmeline PerrialSébastien PapotCharles DumontetBenoît Joseph
Published in: Chemical science (2019)
Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy tissues throughout the body. Pharmacokinetics and tolerability of ADCs are predominantly influenced by the drug-antibody ratio (DAR) of the conjugates, which is to-date limited to a value of 3-4 drugs per antibody in ADCs under clinical investigations. Here, we report the synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous β-glucuronidase-responsive antibody-drug conjugates (ADCs). The highly hydrophilic drug-linker platform described herein improves drug-loading, physicochemical properties, pharmacokinetics and in vivo antitumor efficacy of the resulting conjugates.
Keyphrases
  • cancer therapy
  • drug delivery
  • drug induced
  • gene expression
  • adverse drug
  • randomized controlled trial
  • open label
  • clinical trial
  • emergency department
  • liquid chromatography
  • minimally invasive
  • single cell